BPC-157 and TB-500

BPC-157 is a 15-amino-acid fragment of a protein found in stomach juice. It was first described in 1993 by a research group in Croatia, which has produced most of its studies since.

Most BPC-157 research is in rats, covering tendon, ligament, muscle and gut injury models. Human data is limited to a few small, uncontrolled studies, which puts it at grade C. In July 2026, FDA advisers voted 8–6–1 to recommend letting pharmacies compound it for ulcerative colitis. That vote is advice only, and no final FDA rule had followed by October 2026.

TB-500 is usually a 7-amino-acid fragment of thymosin beta-4, a natural protein that helps cells move by binding actin, part of the cell's internal skeleton. Thymosin beta-4 has been studied in animal models of wound healing and angiogenesis (blood-vessel growth), and the full protein has been tested in human eye-drop trials.

The short TB-500 fragment itself has no human studies (grade D), although FDA advisers voted 8–6–1 in July 2026 to recommend allowing it in pharmacy compounding. In this catalog, TB-500 and TB-500 Frag are the same 7-amino-acid fragment in different fills. Other suppliers sometimes use the name TB-500 for the full 43-amino-acid protein, so always check the certificate for the exact sequence.

The Wolverine blend puts BPC-157 and TB-500 in one vial. The pairing has never been studied, so it is graded D. Both compounds promote angiogenesis in animal studies, and tumors also rely on new blood vessels, so researchers flag a theoretical cancer risk. It is an inference, not an observed effect.